stockrow
Friday 6 November 2026
Export VRTX’s income statement to Excel — free account
Vertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.
- Revenue
- +11.9%
- EPS
- −39.2%
- Free cash flow
- −52.1%
Quarter to September 2026, against a year earlier
547.43
4.93
+0.91%
Follow VRTX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
33.37 | 28.66 | 26.25 | 29.31 |
+8 more quarters Free account |
P/S ratio |
10.23 | 10.01 | 9.29 | 9.66 | |
P/FCF ratio |
41.39 | 33.20 | 30.58 | 36.30 | |
P/Operating CF |
206.08 | 111.98 | 79.45 | 232.78 | |
P/B ratio |
6.34 | 6.22 | 5.86 | 6.21 | |
Price to Tangible BV |
13.30 | 6.72 | 6.35 | 6.76 | |
EV/Sales |
10.04 | 9.42 | 8.73 | 9.14 | |
EV/EBITDA |
28.63 | 23.72 | 21.77 | 25.03 | |
EV/Operating CF |
35.19 | 27.62 | 25.15 | 30.22 | |
EV/FCF |
40.60 | 31.24 | 28.74 | 34.36 | |
Quick Ratio |
1.72 | 2.54 | 2.38 | 2.24 | |
Current Ratio |
2.34 | 3.19 | 3.02 | 2.90 | |
Net Debt/EBITDA |
(3.59) | (6.02) | (6.07) | (5.24) | |
Debt/Assets |
10.68% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.17 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.45 | 0.49 | 0.50 | 0.50 | |
Operating CF/Net income |
0.98 | 1.02 | 1.38 | 0.42 | |
Capex/Depreciation |
(1.41) | (1.99) | (2.39) | (2.68) | |
Interest Coverage |
19.80 | — | — | 120.59 | |
Research and Development Expense of Revenue |
38.38% | 29.81% | 32.19% | 30.52% | |
Selling, General and Administrative Expense of Revenue |
24.53% | 17.46% | 16.53% | 15.27% | |
Intangible Assets out of Total Assets |
0.33 | 0.05 | 0.06 | 0.06 | |
Share Based Compensation of Revenue |
5.07% | 5.11% | 5.57% | 4.94% | |
Graham Net Nets |
0.00 | 0.04 | 0.04 | 0.04 | |
Graham Number |
170.52 | 176.41 | 170.77 | 159.40 | |
Earnings Yield |
3.00% | 3.49% | 3.81% | 3.41% | |
Free Cash Flow Yield |
2.42% | 3.01% | 3.27% | 2.76% | |
Revenue per Share |
13.57 | 13.14 | 11.75 | 12.48 | |
Operating CF per Share |
2.54 | 4.44 | 5.62 | 1.95 | |
Capex per Share |
(0.38) | (0.44) | (0.52) | (0.58) | |
Free Cash Flow per Share |
2.15 | 3.99 | 5.10 | 1.36 | |
Cash per Share |
24.87 | 30.95 | 28.52 | 25.84 | |
Shareholders Equity per Share |
82.48 | 79.81 | 76.20 | 73.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
82.48 | 79.81 | 76.20 | 73.00 | |
Free Cash Flow |
545.80 | 1,013.20 | 1,294.70 | 348.60 | |
Working Capital |
6,686.00 | 8,605.80 | 7,849.70 | 7,339.80 | |
Capital Expenditures |
(97.30) | (112.20) | (133.40) | (149.40) | |
Net Current Asset Value |
(142.60) | 5,368.30 | 4,607.80 | 4,223.80 | |
EV/EBIT |
30.21 | 24.82 | 22.78 | 26.29 | |
Capex to Sales |
0.03 | 0.03 | 0.04 | 0.05 | |
Price to Operating Income |
30.79 | 26.38 | 24.24 | 27.78 | |
| Other line items | |||||
Average Receivables |
2,128.70 | 2,013.90 | 1,900.60 | 1,831.10 | |
Average Payables |
446.45 | 435.90 | 467.15 | 437.35 | |
Average Inventory |
1,936.05 | 1,632.20 | 1,563.20 | 1,446.10 | |
Average Assets |
28,799.30 | 25,730.00 | 24,682.45 | 24,088.10 | |
Average Common Equity |
19,113.10 | 18,711.65 | 17,929.10 | 17,537.70 |
Columns are period end dates · fundamentals updated 5 Nov 2026